Haemonetics (HAE) Stock Looks Reasonable On Cash Flow But Rich On Earnings
Haemonetics stock has nearly doubled over the past year, yet the valuation picture is split, with an intrinsic value estimate pointing to a discount while market multiples lean the other way.
- Haemonetics has returned 90.6% over the past year, which puts extra focus on whether the current price still offers a margin between market value and business fundamentals.
- The recent supply agreement with CSL Plasma may support expectations for future cash flows, while the lack of minimum commitments in that deal leaves uncertainty about how much revenue actually materializes and when.
- A Discounted Cash Flow (DCF) estimate suggests the stock trades about 42.6% below intrinsic value, yet earnings based multiples screen as overvalued and the broader checks give a mixed read, with a 3 out of 6 value score.
The issue now is whether Haemonetics’ current share price better reflects the intrinsic value estimate or the more expensive signal from traditional market multiples.
Compare Haemonetics’ mixed valuation signals with hand-picked companies that pair strong fundamentals with potential upside in the 45 high quality undervalued stocks.
Does Haemonetics Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model values Haemonetics by projecting its future free cash flows and discounting them back to today. For Haemonetics, the model uses latest twelve month free cash flow of about $291 million in US$ and assumes those cash flows continue to grow rather than shrink over time.
On these assumptions, the 2 Stage Free Cash Flow to Equity model arrives at an estimated intrinsic value of about $181 per share. That compares with the current share price, which the DCF suggests is about 42.6% below this estimate, so the stock screens as undervalued on this method. Despite the recent supply agreement with CSL Plasma giving the story more attention, the DCF outcome implies the market price may still lag the value supported by Haemonetics’ projected cash generation.
Overall, the DCF work up indicates Haemonetics stock looks undervalued relative to its estimated intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Haemonetics is undervalued by 42.6%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.
Does Haemonetics Look Pricey on Earnings?
The P/E ratio is a useful cross check for Haemonetics because earnings are a key driver of how investors value this kind of medical equipment stock. Haemonetics currently trades on a P/E of about 49.1x, which is above the Medical Equipment industry average of 26.9x and below the peer group average of 58.4x. On this simple snapshot, the stock sits between the broader sector and a tighter peer set.
A more tailored fair P/E, which looks at Haemonetics’ growth profile, margins, size and risk, is estimated at around 32.8x. That is below the current 49.1x multiple, which indicates a premium over what this framework would suggest as a more balanced valuation level. This gap indicates investors are already paying more for Haemonetics’ earnings relative to both the sector and this fair value marker.
On the P/E multiple, Haemonetics stock currently appears expensive relative to both the industry and its modelled fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
The Haemonetics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Haemonetics' valuation puzzle leaves off by spelling out which future paths for growth, margins and earnings would make the current share price look high or low. Each scenario links its number to a clear view on how Haemonetics' business metrics and risks might evolve, giving you a reference point you can come back to as new information and results are released.
One of the top community narratives on Haemonetics: 21% overvalued
"Heavy reliance on core U.S. markets and short-term gains exposes Haemonetics to competitive, regulatory, and cyclical risks that threaten long-term growth and profitability..."
Read one of the top narratives on Haemonetics
Do you think there's more to the story for Haemonetics? Head over to our Community to see what others are saying!
The Bottom Line
Haemonetics sits between two valuation messages. The Discounted Cash Flow (DCF) work suggests meaningful upside to intrinsic value, while the earnings multiple points to an overvalued stock relative to both peers and a tailored fair P/E. That gap largely reflects different views on cash flow timing and capital needs versus what the market is willing to pay for growth today. The key question from here is whether Haemonetics can convert its cash flow potential into sustained, visible earnings without the risks around concentration and competition turning that apparent discount into a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com